Reprogramming cancer cells to treat an aggressive type of leukemia

by

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

Leave A Comment

Your email address will not be published. Required fields are marked *